McKesson/HBOC sues W3Health, former McKesson employeesFirm claims damages for loss of trade secretsMcKesson/HBOC has filed a lawsuit in Massachusetts Superior Court against W3Health and 12 former McKesson employees for allegedly
Firm claims damages for loss of trade secrets
McKesson/HBOC has filed a lawsuit in Massachusetts Superior Court against W3Health and 12 former McKesson employees for allegedly appropriating trade secrets in connection with a suite of software products, the Clinical Resource Management System (CRMS), developed by the Access Health subsidiary of McKesson. Access Health was rolled into the iMcKesson division in June (HNN 7/12/00).
The lawsuit alleges that W3Health used the proprietary information to develop its own Distributed Reporting System (DRS) software suite that competes directly with CRMS, and that W3Health enticed the 12 employees named in the suit away from McKesson with the specific goal of acquiring the knowledge to create a product similar to CRMS. The San Francisco-based firm seeks damages of triple the amount of monetary damages suffered as a result of W3Health's actions, and enforcement of the noncompete and nondisclosure clauses of the 12 codefendants' employment contracts.
W3Health has issued a release denying McKesson's charges. The firm claims that its ASP-based DRS software does not use any information garnered from McKesson employees in developing its product.
"McKesson/HBOC is using an increasingly common business tactic: suing a potential competitor that has developed a superior product," said Doug Percy, chairman and CEO of Wilmington, MA-based W3Health. "W3Health does not intend to change its business strategy in reaction to this suit."
W3Health launched financial reporting and risk management DRSsoftware commercially in the first quarter of 2000. The firm counts Yale-New Haven PHO as its most recent DRS customer. Other DRSinstallations include Blue Cross/Blue Shield of Vermont, Yale-New Haven Health, New England Medical Center, HealthConnecticut, and Hill Physicians Medical Group.
McKesson/HBOCstock rose following announcement of the lawsuit. After closing at $25.75 per share on Sept. 12, the stock closed at $28 per share on Sept. 13, an increase of 8.7%. Lehman Brothers raised the company's 12-month price target to $34 from $30 on Sept. 8.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.